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We read the interesting pilot study of Dr. Nayot and colleagues on the use of preoperative ^18^F-fluorode-oxyglucose positron emission tomography ([fdg]{.smallcaps}-[pet]{.smallcaps}) with computed tomography ([ct]{.smallcaps}) scanning to detect metastatic nodes in subjects with endometrial cancer[@b1-co16-3-7]. Even though the scanning was not sensitive enough for this purpose, we hypothesize that [fdg]{.smallcaps} itself might actually treat occult micrometastatic disease.

A recent retrospective analysis regarding survival in non-small-cell lung cancer ([nsclc]{.smallcaps}) demonstrated improved survival among patients with stages [iii]{.smallcaps} and [iv nsclc]{.smallcaps} in a [pet]{.smallcaps} scanning period (1999--2004) as compared with a period before [pet]{.smallcaps} scanning (1994--1998)[@b2-co16-3-7]. It was concluded that [fdg]{.smallcaps}-[pet]{.smallcaps} scanning was, in part, independently associated with improved survival because of more sensitive detection of tumour spread, resulting in stage migration. Interestingly and intriguingly, the survival advantage was seen in patients who experienced [fdg]{.smallcaps}-[pet]{.smallcaps} scanning regardless of whether they did or did not undergo chemotherapy or standard radiation therapy.

Although the radiation dose from [fdg]{.smallcaps}-[pet]{.smallcaps} scanning is only a fraction of the standard dose to treat solid tumours[@b3-co16-3-7], perhaps avid uptake of [fdg]{.smallcaps} by metabolically active micrometastatic tumour cells results in highly localized gamma radiation, leading to tumour cell death. Moreover, it is common for lung cancer patients, particularly those with stage [iii]{.smallcaps} or [iv]{.smallcaps} disease to have circulating micrometastatic tumour cells[@b4-co16-3-7], which might explain the improved survival among the patients with stages [iii]{.smallcaps} and [iv nsclc]{.smallcaps} who underwent [fdg]{.smallcaps}-[pet]{.smallcaps} scanning.

Perhaps [fdg]{.smallcaps} should be investigated as a possible treatment modality for micrometastatic tumour burden in various cancers. Furthermore, technologies to determine the presence of micrometastatic disease are available[@b4-co16-3-7],[@b5-co16-3-7], possibly enabling treatments to be more specifically targeted.
